Biosimilars from India: An Emerging Export Category Worth Watching

For buyers who follow pharmaceutical industry trends, India's biosimilar sector is a development worth understanding — even if your immediate procurement focus is on small-molecule generics or surgical supplies. Biosimilars represent a growing category of Indian pharmaceutical exports, and the country's regulatory and manufacturing framework for them has matured significantly.

This post provides an educational overview of what biosimilars are in trade terms, India's regulatory pathway, and what the category means for international buyers.

---

What Is a Biosimilar? (Trade Definition)

A biosimilar is a biological medicine that has been demonstrated to be highly similar to an already approved biological medicine (the "reference biologic" or originator). Unlike small-molecule generic drugs, which can typically be demonstrated equivalent through dissolution and pharmacokinetic testing, biologics are complex molecules produced in living cell systems — making full equivalence demonstration more technically demanding.

The key trade distinction: biosimilars are the biologic equivalent of generics. They become possible when the original biologic's patent and data exclusivity periods expire, and they typically enter the market at lower prices than the originator, improving access.

Common biologic categories where biosimilars are relevant include insulin, monoclonal antibodies, growth factors, erythropoietins, and others. (This post does not discuss the clinical applications of any specific product.)

---

India's Regulatory Pathway for Biosimilars

India's regulatory framework for biosimilars is established under the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules), administered by CDSCO. India also has published Guidelines on Similar Biologics (originally 2012, subsequently updated) that define the data requirements for biosimilar approval — covering quality, preclinical, and clinical comparability studies.

Key features of India's biosimilar pathway: - Biosimilars approved in India must demonstrate comparability to a reference biologic that is approved either in India or by a stringent regulatory authority - The approval pathway involves phased data submission — quality first, then non-clinical, then clinical — with CDSCO review at each stage - Post-approval pharmacovigilance is required

India has been one of the earlier adopters globally of a defined biosimilar regulatory pathway, enabling domestic manufacturers to bring biosimilars to market for both domestic use and export.

---

India's Biosimilar Manufacturing Landscape

India has a growing number of companies with approved or in-development biosimilars — ranging from insulins to immunological products. Several Indian biosimilar manufacturers have also sought approvals in international markets including the EU, USA, and emerging markets.

For export buyers, the relevant questions when evaluating an Indian biosimilar supplier are: - Is the manufacturer CDSCO-approved for this specific biosimilar product? - Does the manufacturer hold or is seeking approval from the importing country's regulatory authority? - What GMP certification does the biologic manufacturing facility hold? (Biologic manufacturing facilities require separate GMP compliance from small-molecule facilities) - Is a product dossier available in CTD format for your country's registration process?

---

What This Means for International Buyers

Biosimilars from India can offer: - Price competitiveness relative to originator biologics - Regulatory pathway clarity in markets that recognise India's approval framework - Growing range of molecules across therapeutic categories

However, biosimilar procurement is more complex than small-molecule generic procurement: - Product registration in the importing country requires significant regulatory investment - Cold chain (typically 2°C–8°C) is nearly universal for biologics, requiring robust logistics planning - Post-marketing pharmacovigilance requirements vary by country

Biosimilar procurement is best approached with experienced regulatory affairs support in the importing country.

---

Bharat Medex and Emerging Categories

Bharat Medex's current core range covers ethical medicines, generic small-molecule formulations, and surgical items — the established categories we have operated in for 19 years. For emerging categories like biosimilars, we encourage buyers to discuss specific product requirements with us directly so we can advise on sourcing options and documentation capability.